Pandion Therapeutics, Inc.
CIK 0001807901Non-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2020
Revenue
$8.78M
Net Income
$-38.10M
Total Assets
$227.86M
Equity
—
Shares Out
29.52M
Op. Cash Flow
$-34.99M
Business
Pandion Therapeutics, Inc. is a former operating company in Pharmaceutical Preparations, incorporated in Delaware. Securities are no longer actively traded on a major U.S. exchange.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|
| Revenue | 9 | 967,000 | |
| Research and development | 34 | 18 | |
| General and administrative | 13 | 5 | |
| Total operating expenses | 47 | 23 | |
| Loss from operations | −38 | −22 | |
| Interest income | 69,000 | 258,000 | |
| Interest expense | −334,000 | −26,000 | |
| Fair value adjustments to convertible note | 89,000 | 110,000 | |
| Net loss | −38 | −22 | |
| Change in redemption value of redeemable convertible preferred shares | −5 | −4 | |
| Net loss attributable to common shares basic and diluted | −43 | −26 | |
| Net loss per common share, basic and diluted | −3.17 | −25 | |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 14 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2020 2020-12-31 | FY 2019 2019-12-31 | FY 2018 2018-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 220 | 16 | — | |
| Accounts receivable | 950,000 | 1 | — | |
| Prepaid expenses and other current assets | 3 | 3 | — | |
| Total current assets | 224 | 20 | — | |
| Property and equipment, net | 3 | 1 | — | |
| Restricted cash | 502,000 | — | — | |
| Total assets | 228 | 21 | — | |
| Accounts payable | 2 | 1 | — | |
| Accrued expenses and other current liabilities | 3 | 1 | — | |
| Current portion of deferred revenue | 4 | 4 | — | |
| Total current liabilities | 9 | 7 | — | |
| Deferred revenue, net of current portion | 4 | 6 | — | |
| Long-term debt, net of issuance costs | — | 4 | — | |
| Other long-term liabilities | 520,000 | 85,000 | — | |
| Total liabilities | 13 | 17 | — | |
| Commitments and contingencies (Note 8) | — | — | — | |
| Redeemable convertible preferred shares, no par value; no shares authorized, issued or outstanding at December 31, 2020; 51,217,321 shares authorized and 35,524,212 shares issued and outstanding at December 31, 2019 | — | 47 | — | |
| Preferred stock, par value $.001 per share: authorized, 5,000,000 shares; none issued | — | — | — | |
| Incentive shares, no par value; no shares authorized, issued or outstanding at December 31, 2020; 7,717,678 shares authorized and 946,751 shares issued and outstanding at December 31, 2019 | — | 172,000 | — | |
| Additional paid-in capital | 301 | — | — | |
| Accumulated deficit | −86 | −43 | — | |
| Total stockholders/members equity (deficit) | 215 | −43 | −17 | |
| Total liabilities, redeemable convertible preferred stock/shares and stockholders/members equity | 228 | 21 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2020 2020-12-31 | FY 2019 2019-12-31 |
|---|---|---|---|
| Depreciation expense | 512,000 | 242,000 | |
| Equity-based compensation expense | 3 | 120,000 | |
| Noncash interest expense | 224,000 | 14,000 | |
| (Gain) loss on disposal of property and equipment | −16,000 | 3,000 | |
| Accounts receivable | 85,000 | −1 | |
| Prepaid expenses and other current assets | −138,000 | −2 | |
| Accounts payable | 492,000 | 358,000 | |
| Accrued expenses and other current liabilities | 2 | 112,000 | |
| Deferred rent | 520,000 | — | |
| Deferred revenue | −3 | 10 | |
| Net cash used in operating activities | −35 | −13 | |
| Purchases of property and equipment | −3 | −635,000 | |
| Net cash used in investing activities | −3 | −635,000 | |
| Proceeds from simple agreement for future equity | 6 | — | |
| Proceeds from issuance of common stock | 153 | — | |
| Proceeds from issuance of long-term debt | — | 2 | |
| Debt issuance costs | — | −104,000 | |
| Repayment of long-term debt | −2 | — | |
| Net cash provided by financing activities | 242 | 20 | |
| Net increase in cash and cash equivalents | 204 | 6 | |
| Cash paid for interest | 50,000 | 4,000 | |
| Conversion of redeemable convertible preferred shares into common stock upon closing of initial public offering | 153 | — | |
| Exchange of JDRF note and accrued interest for Series A redeemable convertible preferred shares | 2 | — | |
| Purchases of property and equipment included in accounts payable | 76,000 | 78,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Pandion Therapeutics, Inc.'s CIK number?
Pandion Therapeutics, Inc.'s SEC CIK number is 0001807901 (1807901). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pandion Therapeutics, Inc.'s SEC filings?
All of Pandion Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.